Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 221,990,854 papers from all fields of science
Search
Sign In
Create Free Account
avagacestat
Known as:
(2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide
, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
BMS 708163
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 5446: Serotonin modulates AKT-mTOR and Notch signaling pathways, promotes liver cancer cell steatosis and cell survival
Suresh Niture
,
Deepak Kumar
Molecular and Cellular Biology / Genetics
2018
Corpus ID: 81039966
The hormone serotonin is known as 5-hydroxytryptamine. It is a precursor of melatonin, derived from the amino acid tryptophan…
Expand
2017
2017
A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human
T. Karelina
,
O. Demin
,
T. Nicholas
,
Yasong Lu
,
S. Duvvuri
,
H. Barton
CPT: Pharmacometrics & Systems Pharmacology
2017
Corpus ID: 21448457
A mechanistic model of amyloid beta production, degradation, and distribution was constructed for mouse, monkey, and human…
Expand
2017
2017
Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
Aitana Sogorb-Esteve
,
M. García‐Ayllón
,
M. Llansola
,
V. Felipo
,
K. Blennow
,
J. Sáez-Valero
Molecular Neurobiology
2017
Corpus ID: 255493988
γ-Secretase inhibitors (GSIs) are potential therapeutic agents for Alzheimer’s disease (AD); however, trials have proven…
Expand
2014
2014
RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE
Nienke M. E. Scheltens
,
B. V. Berckel
,
+4 authors
P. Scheltens
Alzheimer's & Dementia
2014
Corpus ID: 54318871
2014
2014
Synthesis of carbon-14 and stable isotope labeled Avagacestat: a novel gamma secretase inhibitor for the treatment of Alzheimer's disease.
R. Burrell
,
J. Easter
,
M. Cassidy
,
K. Gillman
,
R. Olson
,
S. Bonacorsi
Journal of labelled compounds…
2014
Corpus ID: 32138459
Bristol-Myers Squibb and others are developing drugs that target novel mechanisms to combat Alzheimer's disease. γ-Secretase…
Expand
2013
2013
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
G. Tong
,
Jun-sheng Wang
,
+11 authors
R. Dockens
British Journal of Clinical Pharmacology
2013
Corpus ID: 31772750
AIM To evaluate the single dose pharmacokinetics, pharmacodynamics, and preliminary tolerability of the γ-secretase inhibitor BMS…
Expand
2013
2013
Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data
Camilla Niva
,
Joanna Parkinson
,
Fredrik Olsson
,
E. van Schaick
,
J. Lundkvist
,
S. Visser
European Journal of Clinical Pharmacology
2013
Corpus ID: 253782291
To date, γ-secretase inhibition is the most frequently studied mechanism of reducing Aβ in clinical trials with as yet no…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE